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The Case of Uric Acid*A.J. Marian, MD“I f epidemiologists are compared with ﬁsher-men, causality is the big ﬁsh. It is elusive toﬁnd, difﬁcult to catch, and claims to have
measured it are often exaggerated.” Burgess et al.
(1) were correct: establishing a cause-and-effect rela-
tionship is always challenging. In its purest deﬁni-
tion, analogous elements of the Koch’s postulates of
causality have to be fulﬁlled (2). In its simplistic deﬁ-
nition, the cause has to precede the effect and be
necessary and sufﬁcient for phenotype expression,
albeit with a variable degree of expressivity.
Yet, these extreme deﬁnitions of causality are
seldom germane in genetics. Very few genetic variants
are fully penetrant, independent of the genetic back-
grounds in which they operate (3,4). Fully penetrant
genetic variants are rare in the population, as well as
in each genome, and typically cause familial diseases
that exhibit Mendelian patterns of inheritance.
Strength of evidence for their causality depends not
only on the penetrance but also family size and
structure (number of informative meiosis). Typically,
a genetic variant exhibits incomplete penetrance and
the family size is not large enough to ascertain co-
segregation unambiguously. Therefore, even in single
gene disorders that exhibit Mendelian patterns of in-
heritance, deﬁnite identiﬁcation of the causal gene or
variant remains difﬁcult. The advent of massively
parallel nucleic acid sequencing technologies and the*Editorials published in the Journal of the American College of Cardiology
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netic variants have illustrated overabundance of the
sequence variants in each genome, including in genes
previously implicated in human diseases (5,6). The
plethora of genetic variants renders unequivocal
identiﬁcation of the true disease-causing variant,
even in a single gene disorder, a formidable task.
On the other end of the genetic causality spectrum,
the vast majority of genetic variants that exhibit low
penetrance and exert negligible or modest effect sizes
(2,7). Expectedly, such variants do not exhibit Men-
delian patterns of inheritance but might show aggre-
gation in families or cases with the phenotype of
interest. Evidence of their role in susceptibility to
disease typically originates from genetic epidemio-
logical studies, including genome-wide association
studies (GWAS), showing an excess burden of such
variants in cases as compared to controls. During the
last decade or so, GWAS and candidate gene studies
have identiﬁed a very large number of common var-
iants, deﬁned as a population minor allele frequency
of >1%, associated with cardiovascular phenotypes.
As of February 20, 2015, the last update of the GWAS
catalog, 15,396 single nucleotide polymorphisms
(SNPs) are described in association with various
complex traits. Pertinent to this editorial is the asso-
ciation of serum uric acid levels with more than 40
SNPs in at least 30 genes.
Clinically, an association between serum uric acid
levels and gout as well as hypertension, type II dia-
betes mellitus (T2DM), kidney disease, coronary heart
disease (CHD), and heart failure (HF) has been
recognized and substantiated in numerous modern
epidemiological studies (8). Consequently, serum uric
acid is considered a risk factor for cardiovascular and
metabolic diseases and their clinical outcomes (8).
Conventional epidemiological studies are primarily
observational and subject to confounding effects of
multiple factors, as well as potential biases in study
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418design and reverse causation. Consequently, the
ﬁndings of epidemiological data, whether conven-
tional or GWAS, are vulnerable to confounders and
seriously limited in inferring causality.SEE PAGE 407Considering the shortcomings of the conventional
epidemiological studies, in this issue of the Journal,
Keenan et al. (9) sought to determine the causal role
of serum uric acid in CHD, T2DM, HF, and ischemic
stroke. To reduce effects of potential confounders,
the authors used genetic variants associated with
serum uric acid levels as instrumental variables. The
rationale for using genotypes as instrumental vari-
ables, referred to as Mendelian randomization (MR)
(10), is that genetic variants are assorted randomly
during meiosis, except for variants that are in close
genetic proximity (linkage disequilibrium). There-
fore, confounders are to be distributed randomly
among 3 genotypes of each SNP.
Accordingly, Keenan et al. (9) analyzed the causal
role of 28 SNPs individually and 14 SNPs exclusively
associated with serum uric acid levels (non-
pleiotropic), collectively, as a genetic risk score (GRS)
in cardiometabolic syndromes. To support validity of
the approach, they showed that genetically deter-
mined increased serum uric level was associated with
increased risk of gout, a well-established phenotypic
consequence of hyperuricemia. However, SNPs were
neither individually nor collectively as a GRS associ-
ated with T2DM, CHD, ischemic stroke, or HF. Hence,
the authors speculate that lowering serum uric acid
levels is not expected to improve risk of car-
diometabolic syndromes.
This well-designed and meticulously performed
study beneﬁts from a large study population sample
size, albeit comprised of ethnically mixed populations
with considerable cultural and environmental differ-
ences. The ﬁndings show that a modest shift in serum
uric acid levels is sufﬁcient to increase risk of gout but
not risk of CHD, T2DM, ischemic stroke, or HF. The
rs12498742 SNP at the SLC2A9 locus had the largest
effect size on serum uric acid levels, which was only
0.37 mg/dl, and associated with risk of gout but, once
again, not cardiovascular nor metabolic syndromes.
The small effect size of the genetic variants, typical in
genetic studies of complex traits (11), renders geno-
types as weak instrumental variables. The 14-SNP GRS,
however, shifted serum uric acid levels by 1.4 mg/dl.
Despite the relatively larger effect size compared to
individual SNPs, GRS was associated with gout but not
the selected cardiometabolic phenotypes.
GRS, while beneﬁting from a larger effect size, is
based on numerous assumptions not supported bybiological data. GRSs are particularly speculative
when derived from a diverse group of genes with
multifarious functions and in genetically and envi-
ronmentally heterogeneous populations. Unfortu-
nately, data on serum uric acid levels and the clinical
phenotypes were not consistently available in the
present study populations to assess whether serum
uric levels, independent of the genetic variants, were
associated with the clinical phenotypes.
The present study’s null results regarding serum
uric acid and CHD echo the ﬁndings of a recently
published large-scale MR study in a homogeneous
Danish population (12). Yet another MR study, per-
formed in a population of European origin, with a
study design similar to the present one, concluded
that each 1 mg/dl increase in genetically predicted
uric acid concentration was causally associated with
cardiovascular death and sudden cardiac death (13).
To quote Johann Wolfgang von Goethe, “It’s in
the anomalies that nature reveals its secrets”(14).
A notable example of nature’s anomalies on uric
acid metabolism is Lesch-Nyhan syndrome, an
X-linked disease due to mutations in HPRT (hypo-
xanthine phosphoribosyltransferase 1) gene. It
manifests with severe hyperuricemia since birth,
gout, renal stones, and neurological impairment but
not CHD, T2DM, HF, or ischemic stroke. Perhaps,
despite lifelong exposure, the relatively short life-
span of patients with Lesch-Nyhan syndrome masks
expression of CHD. A few other rare forms of single
gene disorders also cause severe hyperuricemia but
do not express as these cardiovascular diseases.
Collectively, these rare anomalies of nature do not
support a causal role for uric acid in CHD or
ischemic heart disease but there are scant data to
make a ﬁrm conclusion.
Various randomized clinical trials are ongoing to
test beneﬁcial effects of lowering serum uric acid
levels on various cardiovascular phenotypes, with
negative results thus far (15). A beneﬁcial effect, if
observed, would not necessarily indicate a causal
role, as the beneﬁts might result from interventions
modulating various biological effects of uric acid and
the xanthine oxidase metabolic pathway (16), analo-
gous to the beneﬁcial effects of inhibiting the renin-
angiotensin-aldosterone system in HF.
Causality in genetics is seldom deterministic, as it
is in rare large families with single gene disorders. It
is commonly probabilistic, as in complex traits.
Because hyperuricemia does not meet either the strict
Koch’s postulates or simple deﬁnition of causality, it
is not a deterministic cause of the aforementioned
cardiovascular phenotypes. However, uric acid and
the metabolic pathway that generates it are involved
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419in a diverse array of biological functions (15), possibly
contributing to pathogenesis of cardiovascular and
metabolic phenotypes, rendering it pathogenic but
not causal. The results of ongoing randomized clinical
trials might shed some light on serum uric acid’s
pathogenic role in cardiovascular and metabolic
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